Emerald Investment Advisers LLC Invests $5.79 Million in ANI Pharmaceuticals, Inc. $ANIP

Emerald Investment Advisers LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 69,893 shares of the specialty pharmaceutical company’s stock, valued at approximately $5,786,000.

Several other hedge funds also recently added to or reduced their stakes in the business. KBC Group NV purchased a new stake in ANI Pharmaceuticals in the first quarter valued at about $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $28,000. Hantz Financial Services Inc. grew its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $48,000. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals during the second quarter valued at about $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $75.35 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock has a 50-day moving average of $80.36 and a two-hundred day moving average of $78.88. The stock has a market cap of $1.73 billion, a P/E ratio of 16.24 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same period in the prior year, the company earned $1.80 earnings per share. The company’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer owned 174,693 shares in the company, valued at approximately $14,213,022.48. This represents a 1.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares of the company’s stock, valued at $3,144,452.64. This represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,987 shares of company stock worth $1,546,405 in the last ninety days. Corporate insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the subject of several research analyst reports. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Finally, Guggenheim decreased their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.